Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449776 | 0.78 | CA1 (0.54) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL16450789 | 0.76 | KMT2A (0.46) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL12225637 | 0.75 | ALDH1A1 (0.45) | KMT2AALDH1A1LMNASLC22A2SLC22A1 | |
| SCHEMBL12708695 | 0.75 | — | — | |
| SCHEMBL10942900 | 0.74 | KMT2A (0.45) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL17758464 | 0.72 | KMT2A (0.51) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL17758549 | 0.72 | KMT2A (0.44) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL9319541 | 0.72 | KMT2A (0.51) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL16449775 | 0.71 | HPGD (0.42) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL14793401 | 0.70 | ALDH1A1 (0.47) | KMT2ACA12CA9ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745335-B2 | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application | BLIRT S.A. (PL) | 2017-08-29 | — | — | US | disclosed |
| US-9745335-B2 | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application | BLIRT S.A. (PL) | 2017-08-29 | — | — | US | disclosed |
| US-9447136-B2 | Semisynthetic derivatives of Nystatin A1 | BLIRT S.A. (PL) | 2016-09-20 | — | — | US | disclosed |
| US-20150291648-A1 | N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION | BLIRT S.A. (PL) | 2015-10-15 | — | — | US | disclosed |
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | BLIRT S.A. (PL) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | NPC1, NPC1L1, LSS | KMT2A 3736/4885MEN1 130/4885CA12 4179/4885 |
| US-20150291648-A1 | N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION | ERG28, LSS, NPC1 | KMT2A 3056/4885MEN1 577/4885CA12 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.